2016

- Shlobin OA, Nathan SD. Rare ILD and PH. For Pulmonary Hypertension and Interstitial lung disease 2016. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.
- King CS, Nathan SD. Treatment of Pulmonary Hypertension in Interstitial Lung Disease. For Pulmonary Hypertension and Interstitial lung disease 2016. Edited by Robert P. Baughman, Roberto G. Carbone and Steven D. Nathan.

2017


2018


2019


• Aras MA, **Psotka MA**, De Marco T. Pulmonary Hypertension Due to Left Heart Disease: an Update. Curr Cardiol Rep 2020; 21:62.


2020


• King CK, Shlobin OA. The Trouble with Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. Chest 2020 May 7:S0012-3692(20)30872-2. doi: 10.1016/j.chest.2020.04.046.

• Aryal A, King CS. Critical care of patients with pulmonary arterial hypertension. Curr Opin Pulm Med 2020, 26:414–421,

• Khangoora VS, Shlobin OA. Evolving spectrum of treatment for CTEPH. Curr Opin Pulm Med 2020, 26:406–413.


safety and efficacy of pulsed, inhaled nitric oxide (iNO) at a dose of 30 mcg/kg-IBW/hr (iNO 30) in subjects at risk of Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF) receiving Oxygen Therapy. Chest 2020 158:637-645.


2021


